Table 1.
study and year | SAE sample size (Males/Female) |
NE sample size (Males/Female) |
Age | Sample Collection time |
Assay | SAE S100B cutoff (ng/mL) |
Design |
---|---|---|---|---|---|---|---|
Chen 2019 ( 45) | 42(-) All patients: 100(56/44) |
58 (–) | 68 ± 5.4 | ICU admission | ELISA | 0.53 ± 0.28 | NA |
Cui 2022 ( 46) | 79(45/34) | 121(70/51) | SAE:72.78 ± 4.01 NE:72_86 ± 4.60 |
Within 48 h | FICA | 0.53 ± 0.09 | Retrospective study |
Erikson 2019 ( 29) | 10(4/6) | 12(10/2) | SAE: 62.4 (49‐70.5) NE: 61.8 (60.1‐78.5) |
When CAM‐ICU assessed | CLIA | 0.30 (0.19‐0.59) | Prospective observational study |
Feng 2017 ( 31) | 36(21/15) | 23(14/9) | SAE:52 ± 14 NE:57 ± 15 |
1,3 d | CLIA | 1d:0.33(0.15,0.54) 3d:0.19(0.10,0.29) |
Retrospective study |
Guo 2021 ( 26) | 30(17/13) | 90(42/48) | SAE:57.61 ± 4.16 NE:56.91 ± 4.85 |
NA | ELISA | 0.27 ± 0.06 | NA |
Hamed 2009 ( 25) | 16(-) All patients: 40(24/16) |
24(-) | 51.75 ± 4.09 months | NA | ELISA | 0. 24 ± 0.07 | NA |
Hu 2020 ( 47) | 40(-) | 40(-) | NA | 1 h,3 d,5 d | ELISA | 1h:0.50351 ± 0.41551 3d:0.36315 ± 0.2466 5d:0.0683 ± 0.02235 |
NA |
Jiang 2021 ( 35) | 26(18/8) | 38(27/11) | SAE:42.45 ± 3.48 NE:41.2 ± 3.5 |
4 h | ELISA | 0.16446 ± 0.02921 | Retrospective study |
Kang 2022 ( 40) | 22(14/8) | 25(14/11) | SAE:27.5(11.3-54.5)months NE:21.0(9.0-32.5)months |
Within 24 h | ELISA | 1.8 ± 0.2 | Retrospective study |
Li 2019 ( 42) | 28(-) All patients: 100(56/44) |
102(-) | 58.6 ± 6.7 | 1 d | ELISA | 0.92 ± 0.15 | Retrospective study |
Li 2022 ( 23) | 21(13/8) | 20(12/8) | SAE: 37 ± 5 NE: 38 ± 4 |
12,24,48 h | NA | 12h:2.38 ± 0.21 24h:3.52 ± 0.16 48h:2.45 ± 0.18 |
Retrospective study |
Liao 2017 ( 37) | 28(20/8) | 10(8/2) | SAE: 55 ± 13 NE: 51 ± 16 |
1 h,3 d | ELISA | 1h: 0.5 ± 0.24 3d:0.58 ± 0.33 |
NA |
Lu 2016 ( 27) | 34(24/10) | 52(33/19) | SAE: 59.15 ± 8.8 NE: 58.39 ± 8.14 |
NA | NA | 1.21 ± 0.15 | Retrospective study |
Nguyen 2014 ( 33) | 107 (-) All patients: 128(83/45) |
21(-) | 65 ± 14 | ICU admission,4 d | RIA | ICU admission:0.13 (0.06, 0.49) 4d:0.12 (0.08, 0.24) |
Prospective observational study |
Pfister 2008 ( 34) | All patients: 16(10/6) |
NA | 73.08 ± 8.78 | NA | CLIA | NA | NA |
Wang 2019 ( 48) | 48(20/28) | 12(7/5) | SAE: 55 ± 13 NE: 56 ± 7 |
1 h,3 d | ELISA | NA | NA |
Wang 2020 ( 41) | 30(17/13) | 30(19/11) | SAE: 50.5 ± 2.3 NE: 50.8 ± 2.5 |
1 d | WB | 0.28 ± 0.04 | NA |
Wang 2022 ( 49) | 45(29/16) | 35(22/13) | SAE:55.42 ± 14.63 NE: 56.37 ± 15.74 |
1 d,3 d | ELISA | 1d:0.32(0.162, 0.579) 3d:0.18(0.116, 0.307) |
NA |
Wu 2020 ( 30) | 59(38/21) | 45(32/13) | SAE: 54 ± 15 NE: 58 ± 14 |
1,3d | ECLIA | 1d:0.291(0.174–0.478) 3d:0.226(0.129–0.447) |
Prospective and cohort study |
Yan 2019 ( 28) | 58(44/14) | 94(60/34) | SAE: 55.8 ± 16.4 NE: 55.0 ± 18.3 |
Within 24 h | ELISA | 0.5(0.3, 1.3) | Retrospective study |
Yao 2014 ( 24) | 48(33/15) | 64(40/24) | SAE: 56 ± 16 NE: 52 ± 17 |
1 d | ECLIA | 0.306 (0.157,0.880) | Prospective observational study |
Yu 2020 ( 39) | 90(49/41) | 90(47/43) | SAE: 53.61 ± 12.74 NE: 52.89 ± 11.65 |
NA | ELISA | 0.96 ± 0.14 | NA |
Yu 2022 ( 38) | 67(37/30) | 95(51/44) | SAE:70.3 ± 8.3 NE: 69.7 ± 8.6 |
NA | ICA | 1.03 ± 0.32 | Retrospective study |
Zhang 2015 ( 36) | 38(24/14) | 36(22/14) | SAE:56 ± 17 NE: 54 ± 15 |
1 d | ELISA | 1.81 ± 0.22 | Prospective study |
Zhang 2016 ( 32) | 29(20/9) | 28(13/15) | SAE:55.55 ± 12.72 NE: 56.21 ± 12.85 |
Within 24 h | ELISA | 2.50 ± 0.49 | Prospective observational study |
Zhao 2016 ( 44) | 56(30/26) | 60(32/28) | SAE:47 ± 13.4 NE: 49 ± 13.2 |
ICU admission | ELISA | 0.775 ± 0.356 | NA |
Zhao 2020 ( 43) | 22 (–) All patients: 100(58/42) |
78 (–) | 65.3 ± 12.1 | 1 d | ELISA | 0.92 ± 0.11 | NA |
Zhao 2022 ( 50) | 28(16/12) | 32(18/14) | SAE:55.89 ± 16.55 NE: 55.23 ± 16.71 |
NA | ELISA | 0.99 ± 0.28 | NA |